Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan
Date
2012
Authors
Yoshida, C.
Fletcher, L.
Ohashi, K.
Wakita, H.
Kumagai, T.
Shiseki, M.
Matsuei, K.
Inokuchi, K.
Hatta, Y.
Shirasugi, Y.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
International Journal of Clinical Oncology, 2012; 17(6):584-589
Statement of Responsibility
Chikashi Yoshida, Linda Fletcher, Kazuteru Ohashi, Hisashi Wakita, Takashi Kumagai, Masayuki Shiseki, Kousei Matsuei, Koiti Inokuchi, Yoshihiro Hatta, Yukari Shirasugi, Toshikazu Yamaguchi, Junichi Sakamoto, Susan Branford, Hisashi Sakamaki
Conference Name
Abstract
BACKGROUND: Real-time quantitative polymerase chain reaction (RQ-PCR) has been widely used for molecular monitoring for patients with chronic myeloid leukemia (CML). Currently, RQ-PCR is not based on the concept of international scale (IS) in Japan; mainly because none of the domestic laboratories have obtained their own conversion factor (CF) which makes it possible to convert locally scaled BCR-ABL (BCR-ABL (L)) value to the IS (BCR-ABL (IS)). To join the global trend of molecular assessment of BCR-ABL in CML patients, we have tried to obtain a CF in Japan. METHODS: Samples from 55 patients were exchanged between the Japanese laboratory and the reference laboratory in Adelaide, and BCR-ABL and internal control gene transcripts of the samples were measured using RQ-PCR. The patient bias conversion method was used to determine the CF for the IS using the Bland and Altman method. RESULTS: The local CF in the Japanese laboratory was determined to be 0.87. Based on this CF, 0.1% BCR-ABL (IS), defined as major molecular response, becomes equivalent to 731 copy/μg RNA BCR-ABL (L). CONCLUSION: This study is the first to introduce a laboratory-specific CF for harmonizing RQ-PCR methodology for detecting BCR-ABL transcripts to Japan, which may open new windows for molecular assessment of CML patients in Japan.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© Japan Society of Clinical Oncology 2011